Daily non-political popular news in brief.

Monoclonal Antibody Reduces Exacerbations In Asthmatics, Study Finds

10-10-2006 · ScienceDaily

Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo. This research appears in the first issue for October 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Keywords: monoclonal, antibody, exacerbations, asthmatics, study, exacerbation, asthmatic

« Previous | Next »

Similar news on "Monoclonal Antibody Reduces Exacerbations In Asthmatics, Study Finds":

Preventing lung scarring may extend lives of lung cancer patients
10-29-2007 · EurekAlert!
Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients -- pulmonary fibrosis -- thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on Oct. 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
Similar news · Read more »
Asthmatic children still not breathing easier, study says
03-15-2007 · EurekAlert!
Only 20 percent of children with persistent asthma have a level of control that is optimal, according to a study published today in the journal of Ambulatory Pediatrics.The study revealed that 37 percent received no preventive medication, despite current guidelines that recommend it to all children with persistent asthma; shockingly, another 43 percent did receive medications, but were still troubled by poor symptom control, regardless of the child's age or the household's income level.
Similar news · Read more »
Cancer treatment targets tumor blood supply in patients
03-02-2007 · EurekAlert!
An antibody called J591 specifically targets an antigen found in high amounts on both prostate tumors and on blood vessels of all solid tumors, according to a study by researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Similar news · Read more »
Other highlights in the November 1 JNCI
10-31-2006 · EurekAlert!
Other highlights in the November 1 issue of JNCI include a review of statins and fibrates for action against melanoma, a study of a virus that kills brain tumors in mice, an antibody that decreases ovarian cancer growth in mice and a study that describes the use of the immunohistochemical assay in predicting clinical trial results for breast cancer patients.
Similar news · Read more »
PET imaging identifies aggressive kidney cancers that require surgery
03-06-2007 · EurekAlert!
A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma -- the most common and aggressive type of renal tumor -- and arms the urologist with crucial information that will help determine whether surgery is needed.
Similar news · Read more »
Antibody reduces incidence of acute rejection in high-risk kidney transplant patients
11-08-2006 · EurekAlert!
Nearly 70 percent of kidney transplant patients get short-term drug therapy initially administered during surgery to help prevent rejection. In the first direct comparison of the two drugs most commonly given to ward off acute kidney rejection, an international study led by Washington University School of Medicine in St. Louis shows that one -- anti-thymocyte globulin -- is superior. The results also suggest the drug could potentially save millions of dollars in health care costs.
Similar news · Read more »
Patients respond well to first study to test higher doses of an anti-cancer drug
11-10-2006 · EurekAlert!
Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
Similar news · Read more »
Jefferson researchers boost immune 'killer cells,' increase antibody effectiveness against cancer
04-18-2007 · EurekAlert!
Researchers have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body. They have shown in laboratory studies that adding such cells to anti-cancer therapies involving monoclonal antibody drugs such as Herceptin, which targets the HER2/neu protein on breast cancer cells, is more effective in killing cancer cells, and perhaps someday may improve treatments.
Similar news · Read more »
Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
10-09-2007 · EurekAlert!
Mayo Clinic researchers have found that a human antibody administered in a single low dose in laboratory mouse models can repair myelin, the insulating covering of nerves that when damaged can lead to multiple sclerosis and other disorders of the central nervous system.
Similar news · Read more »
MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
10-29-2007 · EurekAlert!
MedImmune today announced results from a recent economic analysis of Synagis (palivizumab), a monoclonal antibody that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus in high-risk infants. Released at the American Academy of Pediatrics 2007 National Conference and Exhibition, the analysis evaluated the costs of providing Synagis to premature infants, as well as the potential health benefits and cost savings that could occur from lower rates of severe RSV infections.
Similar news · Read more »